Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPOX in gastric cancer. Immune checkpoint inhibitors have revolutionized the cancer treatment paradigm. These agents modulate the tumor microenvironment or other aspects of the immune system to overcome the immune suppression that a tumor elicits on the host immune system. Anti-PD-1/programmed cell death ligand-1 (PD-L1) agents target immunosuppressive pathways and have been shown to be beneficial in numerous tumor types.

Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPDX in gastric cancer.